Evaluation of BMS-986142, a reversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study

Conaghan, PG orcid.org/0000-0002-3478-5665, Nowak, M, Du, S et al. (7 more authors) (2023) Evaluation of BMS-986142, a reversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study. The Lancet Rheumatology, 5 (5). e263-e273. ISSN 2665-9913

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Dates:
  • Accepted: 14 March 2023
  • Published (online): 24 April 2023
  • Published: May 2023
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Musculoskeletal Medicine & Imaging (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 22 May 2023 10:29
Last Modified: 25 Jun 2023 23:21
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1016/s2665-9913(23)00089-9

Export

Statistics